MediumCardiologyHeart failure with reduced ejection fractionca-mccqe1ca-rcpsc-im
A 64-year-old man with ischaemic cardiomyopathy (LVEF 30%) and NYHA class II symptoms is on an ACE inhibitor and a guideline-recommended beta blocker at target doses. His blood pressure is 118/70 mm Hg, potassium 4.5 mmol/L and eGFR 65 mL/min/1.73 m2. According to contemporary Canadian heart failure recommendations, which additional class of drug is now considered part of foundational therapy for HFrEF?